Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing treatment with clozapine

R R Conley1

  • 1Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA.

The Journal of Clinical Psychiatry
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of the special patient with schizophrenia.

Dialogues in clinical neuroscience·2011
Same author

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

The pharmacogenomics journal·2009
Same author

ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf.

Molecular psychiatry·2005
Same author

Assessment of capacity to give consent to research participation: state-of-the-art and beyond.

Journal of health care law & policy·2004
Same author

Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement.

Human psychopharmacology·2003
Same author

Management of treatment resistance in schizophrenia.

Biological psychiatry·2001
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Clozapine is a highly effective treatment for resistant schizophrenia, offering significant benefits despite potential side effects. Optimal dosing and monitoring are key to maximizing its favorable risk-benefit profile for patients.

Area of Science:

  • Pharmacology
  • Psychiatry

Background:

  • Clozapine is the sole effective antipsychotic for treatment-resistant schizophrenia.
  • It exhibits superior efficacy and fewer extrapyramidal side effects compared to conventional antipsychotics.
  • Underutilization may stem from underappreciation of its risk-benefit ratio and restricted indication.

Purpose of the Study:

  • To highlight clozapine's efficacy in treatment-resistant schizophrenia.
  • To discuss its risk-benefit profile and management strategies.
  • To emphasize the importance of individualized dosing and monitoring.

Main Methods:

  • Review of clozapine's efficacy and safety data.
  • Discussion of clinical guidelines and patient management.
  • Analysis of side effects and risk mitigation strategies.

Related Experiment Videos

Main Results:

  • Clozapine significantly improves psychiatric well-being and reduces hospital readmissions.
  • Severe side effects like agranulocytosis are manageable with safety measures.
  • Optimal plasma levels (200-350 ng/mL) and daily doses (200-400 mg) aid in maximizing benefits and minimizing risks.
  • Discontinuation can lead to high relapse rates (up to 80%).

Conclusions:

  • Clozapine offers a favorable risk-benefit ratio for treatment-resistant schizophrenia when managed appropriately.
  • Individualized dosing, plasma level monitoring, and continued treatment are crucial for sustained efficacy.
  • Safety measures have significantly reduced mortality from clozapine-induced agranulocytosis.